Terkko Navigator / Reitamo, S.

The Value of Filaggrin Null Mutations in Predicting Treatment Response in Atopic Dermatitis: An Observational Study in Finnish Patients.

Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5).

MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): The new generation guideline implementation.

High Serum Total IgE Predicts Poor Long-term Outcome in Atopic Dermatitis.

Comparison of Moisturizing Creams for the Prevention of Atopic Dermatitis Relapse: a Randomized Double-Blind Controlled Multicentre Clinical Trial.

An update on current pharmacotherapy options in atopic dermatitis.

Long-term Safety of Topical Pimecrolimus and Topical Tacrolimus in Atopic Blepharoconjunctivitis.

Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs.

Atopic dermatitis: a candidate for disease-modifying strategy.

Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two-year open-label study.

MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine.

Leg ulcers treated with topical tacrolimus in patients with rheumatoid arthritis.

The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle-controlled study.

Effect of oral acetylsalicylic Acid on burning caused by tacrolimus ointment in patients with atopic dermatitis.

A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years.

One-year Treatment with 0.1% Tacrolimus Ointment versus a Corticosteroid Regimen in Adults with Moderate to Severe Atopic Dermatitis: A Randomized, Double-blind, Comparative Trial.

Tacrolimus ointment in atopic blepharoconjunctivitis does not seem to elevate intraocular pressure.

Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: Results from two randomized, multicentre, comparative studies.

Long-term safety of tacrolimus ointment in atopic dermatitis.

Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial.

The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis*.

Hit early and hit hard in atopic dermatitis and not only in asthma.

Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study.

A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients.

Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment.

IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis.

Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment.

Recall antigen reactions in patients with atopic dermatitis treated with tacrolimus ointment for 1 year.

Long-term Follow-up of Cancer Risk in Patients Treated with Short-term Cyclosporine.

Topical tacrolimus in the treatment of atopic dermatitis-does it benefit the airways? A 4-year open follow-up.

Long-term Treatment with 0.1% Tacrolimus Ointment in Adults with Atopic Dermatitis: Results of a Two-year, Multicentre, Non-comparative Study.

13-cis-Retinoic acid therapy induces insulin resistance, regulates inflammatory parameters, and paradoxically increases serum adiponectin concentration.

Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients.

Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study.

Respiratory symptoms, bronchial hyper-responsiveness, and eosinophilic airway inflammation in patients with moderate-to-severe atopic dermatitis.

Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial.

A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis.

The role of topical calcineurin inhibitors in atopic dermatitis.

Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis.

An economic evaluation of intermittent cyclosporin A therapy versus UVAB phototherapy in the treatment of patients with severe atopic dermatitis.

0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.

Atopic dermatitis management with tacrolimus ointment (Protopic).

Tacrolimus and pimecrolimus ointments in the treatment of atopic eczema

Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis.

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis.

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis.

Treatment of lichenified atopic eczema with tacrolimus ointment.

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.

Itch in atopic dermatitis.

Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5).